YJYewei Ji

Yewei Ji

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yewei Ji has a total of 89 co-authors. Here are the top co-authors by number of shared publications:

  • Tingbo Liang

    Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China

    4 shared publications
  • Zhangsen Zhou

    Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China

    4 shared publications
  • Lei Chang

    Zhejiang Provincial Key Laboratory of Pancreatic Disease, MOE Joint International Research Laboratory of Pancreatic Diseases & Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

    3 shared publications
  • Ling Qi

    Department of Molecular Physiology and Biological Physics, University of Virginia School of Medicine, Charlottesville, USA

    3 shared publications
  • Mengqi Sun

    Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

    3 shared publications
  • Zinan He

    Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

    3 shared publications

Latest Publications

  • Open Access

    ACAT1/SOAT1 governs mitochondrial dynamics and thermogenesis via the mTOR-MFN2-USP2 axis in brown adipocytes

    by Wei Duan, Mengyao Wang, Yaming Yuan, Yufeng Zhang, Wei Jiao, Nan Wang, Ping Yang, Xuelian Xiong, Shuang Tang, Yufei Gao, et al.

  • Hepatocyte hnRNPK preserves mitochondrial integrity to restrain liver injury and fibrosis

    by Qian Peng, Sujuan Wang, Yufeng Zhang, Yangjun Luo, Beiwu Lan, Nan Wang, Wei Jiao, Zhiqin Xie, Yaming Yuan, Wei Duan, et al.

    Background and Aims: Liver fibrosis is a global health issue with unclear unified drivers. The RNA-binding protein hnRNPK is critical for hepatic homeostasis, but its role in chronic fibrosis remains undefined. This study investigated hnRNPK-mediated splicing dysregulation in liver fibrosis and its therapeutic potential. Approach and Results: We mapped hepatocellular hnRNPK expression across a broad spectrum of human and murine fibrotic etiologies. Mechanistic insights were obtained by integrating snRNA-seq, hepatocyte-specific alternative splicing profiling, untargeted and spatial metabolomics, and 3D mitochondrial reconstruction using AT-SEM. We identified reduced hepatocellular hnRNPK abundance as a conserved hallmark of liver fibrosis across distinct pathogenic insults, including MASH, ALD, HBV, and DILI. Hepatocyte-specific Hnrnpk ablation in mice induced aberrant Opa1 splicing, specifically promoting exon 4b inclusion. This disrupted the balance of OPA1 isoforms, depleting L-OPA1 and driving severe mitochondrial fragmentation characterized by distinct “spheroid” ultrastructures. This loss of mitochondrial integrity triggered HSC activation through the cytosolic mtDNA–cGAS–STING pro-inflammatory signaling cascade and the mitochondria-containing pellet. Notably, restoring the hnRNPK– Opa1 axis via AAV-mediated overexpression of Hnrnpk or the Opa1 -Δ4b isoform (lacking exon 4b), together with pharmacological promotion of mitochondrial fusion, effectively arrested and regressed established liver fibrosis in multiple murine models. Conclusions: Our findings establish the loss of hnRNPK as a central, unifying mechanism in liver fibrogenesis. By governing the Opa1 splicing axis, hnRNPK maintains mitochondrial integrity and prevents the pro-inflammatory signaling and secretome that fuel HSC activation. Targeting this RNA–mitochondria axis represents a potent, etiology-independent therapeutic strategy for chronic liver disease.


  • Identification of D4 as a novel antiviral compound inhibiting hepatitis B virus surface antigen via TMEM40 upregulation

    by Shao-Yuan Long, Shi-Han Zhou, Chu-Jun Zhong, Ye-Wei Ji, Ai-Long Huang, Jie-Li Hu

  • Open Access

    Identification of D4 as a Novel Antiviral Compound Inhibiting Hepatitis B Virus Surface Antigen via TMEM40 Upregulation

    by 少媛 龙, Shi-Han Zhou, Chu-Jun Zhong, Ye-Wei Ji, Ailong Huang, Jieli Hu

    Chronic hepatitis B virus (HBV) infection poses a significant global public health challenge. Current therapies rarely achieve a functional cure, defined as the clearance of hepatitis B surface antigen (HBsAg) and fulfillment of other criteria. A critical unmet need is the development of agents that effectively suppress HBsAg production. Notably, serum HBsAg in patients predominantly originates from subviral particles (SVPs).To identify compounds inhibiting SVP production, we previously developed a cell model (HepG2-S-HiBiT) secreting HiBiT-tagged HBsAg, enabling high-throughput screening. Using this model, we screened a library comprising more than 5,000 compounds and identified a hit compound (Compound 1) that potently inhibited HBsAg production. Subsequent structural optimization yielded a lead derivative, designated D4.In vitro cellular assays confirmed that D4 suppresses HBsAg production through a transcription-dependent mechanism. Transcriptomic profiling further revealed that Transmembrane Protein 40 (TMEM40) is significantly upregulated following D4 exposure. Subsequent mechanistic investigations established that TMEM40 exerts anti-HBV activity via activation of the JAK–STAT signaling pathway. Collectively, our findings demonstrate that D4 represents a promising lead scaffold for the development of novel anti-HBV therapeutics, exerting its antiviral effects by upregulating TMEM40 and subsequently activating the JAK–STAT pathway to suppress viral transcription.

  • Open Access

    Ubiquitination by HRD1 is essential for TLR3 trafficking and its innate immune signaling

    by Lianfeng Zhao, Zinan He, Yao Sun, Mengqi Sun, Zheyi Liu, Zhangsen Zhou, Ling Qi, Yuan Luo, Yewei Ji, Tingbo Liang

    Toll-like receptor 3 (TLR3), an innate immune sensor for double-stranded RNA (dsRNA), traffics from the endoplasmic reticulum (ER) after synthesis to endolysosomes for proteolytic cleavage and activation. However, the molecular mechanisms governing TLR3 trafficking remain largely unclear. Here, we identify the ER-resident E3 ligase HMG-CoA reductase degradation protein 1 (HRD1), a core component of ER-associated degradation (ERAD), as a key regulator that promotes TLR3 trafficking and downstream signaling. HRD1 deficiency in macrophages significantly impairs poly(I:C)-induced TLR3 signaling and inflammatory responses in vitro and in vivo, caused by a marked reduction in TLR3 transport into endolysosomes and subsequent proteolytic processing. Mechanistically, HRD1 mediates ubiquitination of ER-localized TLR3 at lysine 813, which is required for its recognition and sorting by the endosomal sorting complex required for transport (ESCRT) machinery. This HRD1 function is decoupled from its canonical ERAD activity and the ER stress sensor inositol-requiring enzyme 1 alpha (IRE1α). Hence, our study identifies a previously unrecognized mechanism controlling TLR3 signaling and links HRD1-mediated ubiquitination to immune sensor trafficking during innate immune responses.


  • Open Access

    IRE1α translational suppression potentiates STING-dependent chemoresistance in pancreatic cancer

    by Yuan Luo, Mengqi Sun, Lei Chang, Zinan He, Xinghang Zhou, Yaming Yuan, Huijuan Sun, Shiqi Luo, Jinyan Huang, Hongkun Wu, et al.

    Chemotherapy remains a standard treatment for pancreatic ductal adenocarcinoma (PDAC); however, its effectiveness is limited, and the underlying mechanisms are poorly understood. STING plays diverse and critical roles in cancer, yet the role of PDAC cell-intrinsic STING signaling and its regulation under chemotherapy remain unclear. Here, we report that chemotherapy induces cancer cell-intrinsic STING signaling and that STING deletion in PDAC enhances cell death under chemotherapy while suppressing tumor growth in both immune-deficient and immune-competent mice. Interestingly, chemotherapy selectively inhibits translation of IRE1α, an ER membrane protein and a canonical mediator of ER stress. Loss of IRE1α in PDAC amplifies STING signaling and increases resistance to chemotherapy. Mechanistically, IRE1α interacts with STING via their transmembrane regions, reducing STING stability in PDAC cells. Our study reveals that PDAC cells downregulate IRE1α to reinforce STING-mediated pro-survival response; however, this adaptation also makes them more vulnerable to proteostasis imbalance and ER stress-induced cell death. Notably, we demonstrate that combining ER stress inducers with STING signaling inhibition enhances chemotherapy efficacy both in vitro and in vivo.


  • ER: a critical hub for STING signaling regulation

    by Yuan Luo, Lei Chang, Yewei Ji, Tingbo Liang


  • Open Access

    SEL1L–HRD1 endoplasmic reticulum-associated degradation controls STING-mediated innate immunity by limiting the size of the activable STING pool

    by Yewei Ji, Yuan Luo, Yating Wu, Yao Sun, Lianfeng Zhao, Zhen Xue, Mengqi Sun, Xiaoqiong Wei, Zinan He, Shuangcheng Alivia Wu, et al.

    Stimulator of interferon genes (STING) orchestrates the production of proinflammatory cytokines in response to cytosolic double-stranded DNA; however, the pathophysiological significance and molecular mechanism underlying the folding and maturation of nascent STING protein at the endoplasmic reticulum (ER) remain unknown. Here we report that the SEL1L–HRD1 protein complex—the most conserved branch of ER-associated degradation (ERAD)—is a negative regulator of the STING innate immunity by ubiquitinating and targeting nascent STING protein for proteasomal degradation in the basal state. SEL1L or HRD1 deficiency in macrophages specifically amplifies STING signalling and immunity against viral infection and tumour growth. Mechanistically, nascent STING protein is a bona fide substrate of SEL1L–HRD1 in the basal state, uncoupled from ER stress or its sensor inositol-requiring enzyme 1α. Hence, our study not only establishes a key role of SEL1L–HRD1 ERAD in innate immunity by limiting the size of the activable STING pool, but identifies a regulatory mechanism and therapeutic approach to targeting STING.


  • Toll-like receptors TLR2 and TLR4 block the replication of pancreatic β cells in diet-induced obesity

    by Yewei Ji, Shengyi Sun, Neha Shrestha, Laurel B. Darragh, Jun Shirakawa, Yuan Xing, Yi He, Bethany A. Carboneau, Hana Kim, Duo An, et al.

    Consumption of a high-energy Western diet triggers mild adaptive β cell proliferation to compensate for peripheral insulin resistance; however, the underlying molecular mechanism remains unclear. In the present study we show that the toll-like receptors TLR2 and TLR4 inhibited the diet-induced replication of β cells in mice and humans. The combined, but not the individual, loss of TLR2 and TLR4 increased the replication of β cells, but not that of α cells, leading to enlarged β cell area and hyperinsulinemia in diet-induced obesity. Loss of TLR2 and TLR4 increased the nuclear abundance of the cell cycle regulators cyclin D2 and Cdk4 in a manner dependent on the signaling mediator Erk. These data reveal a regulatory mechanism controlling the proliferation of β cells in diet-induced obesity and suggest that selective targeting of the TLR2/TLR4 pathways may reverse β cell failure in patients with diabetes.